| Relatlimab | ONO-4482; BMS-986016 | Phase 3 Clinical | Bristol-Myers Squibb Company | Adenocarcinoma; Brain metastases; Brain Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Glioblastoma; Gliosarcoma; Hematologic Neoplasms; Hodgkin Disease; Large intestine neoplasm; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male Urogenital Diseases; Melanoma; Microsatellite instability-high cancer; Multiple Myeloma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms; Uveal melanoma | Details |
| Fianlimab | REGN-3767 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
| Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Mavezelimab/Pembrolizumab | MK-4280A; MK-4820A | Phase 3 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | Details |
| SHR-1802 | SHR-1802 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | | Details |
| Tobemstomig | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Liver Neoplasms; Melanoma; Solid tumours | Details |
| Alcestobart | LBL-007 | Phase 2 Clinical | Leads Biolabs Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Negalstobart | IBI-110 | Phase 2 Clinical | | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Neoplasms; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Mavezelimab | MK-4280 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Small Cell Lung Carcinoma | Details |
| Ieramilimab | IMP-701; LAG-525 | Phase 2 Clinical | Immutep | Esophageal adenocarcinoma; Lymphoma, Large B-Cell, Diffuse; Melanoma; Ovarian Neoplasms; Persistent Fetal Circulation Syndrome; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Miptenalimab | BI-754111 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| AK-129 | AK-129 | Phase 2 Clinical | | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| HLX-26 | HLX-26 | Phase 2 Clinical | | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lymphoma; Solid tumours | Details |
| GLS-012 | GLS-012 | Phase 2 Clinical | Harbin Gloria Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| EMB-02 | EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | | Details |
| DNV-3 | DNV-3; DNV3 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Lymphoma; Melanoma; Neoplasms; Skin Neoplasms; Solid tumours | Details |
| KL-A289 | KL-A289 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | | Details |
| Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| IMP-761 | IMP-761 | Phase 1 Clinical | Immutep | | Details |
| Sym-022 | Sym-022; Sym022; S95017 | Phase 1 Clinical | Symphogen A/S | Lymphoma; Neoplasm Metastasis; Solid tumours | Details |
| MIL-98 | MIL-98 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Breast Neoplasms; Lymphoma; Melanoma; Solid tumours | Details |
| AN-8025 | AN-8025 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | | Details |
| ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio Inc | | Details |
| TQB-2252 | TQB-2252; TQB2252 | Phase 1 Clinical | Chia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd | | Details |
| AK-137 | AK137; AK-137 | Phase 1 Clinical | | | Details |
| SSGJ-709 | SSGJ-709; SSGJ709 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | | Details |
| JY-03 | JY03; JY-03 | Phase 1 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | | Details |
| ZGGS-15 | ZGGS15; ZGGS-15 | Phase 1 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | | Details |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | | | Details |
| Encelimab | TSR-033; TSR 033; TSR033; GSK-4074386 | Phase 1 Clinical | Anaptysbio Inc | | Details |
| 68Ga-DOTA-hLAG-3 | | Clinical | The First Affiliated Hospital Of Xiamen University | | Details |